Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic protozoans (a group of single-celled microorganisms) belonging to the Plasmodium type. In severe cases it can cause yellow skin, seizures, coma, or death. The disease is widespread in the tropical and subtropical regions that exist in a broad band around the equator. This includes much of Sub-Saharan Africa, Asia, and Latin America. In 2015, there were 214 million cases of malaria worldwide resulting in an estimated 438,000 deaths, 90% of which occurred in Africa. Rates of disease have decreased from 2000 to 2015 by 37%, but increased from 2014 during which there were 198 million cases. Malaria is commonly associated with poverty and has a major negative effect on economic development.
Economic impact and protection
In Africa, it is estimated to result in losses of US$12 billion a year due to increased healthcare costs, lost ability to work, and negative effects on tourism. Immunity (or, more accurately, tolerance) to P. falciparum malaria does occur naturally, but only in response to years of repeated infection. An individual can be protected from a P. falciparum infection if they receive about a thousand bites from mosquitoes that carry a version of the parasite rendered non-infective by a dose of X-ray irradiation. A vaccine against malaria called RTS,S, was approved by European regulators in 2015. It is undergoing pilot trials in select countries in 2016. The highly polymorphic nature of many P. falciparum proteins results in significant challenges to vaccine design.
CompoVax malaria vaccine composition
Variations of the platform DNA vaccine against P. falciparum include linked sequences encoding an extracellular domain of Thrombospondin Related Adhesive Protein (TRAP), Circumsporozoite Protein (CSP) and a proprietary protein allowing intracellular transfer of the fusion antigen. CSP and TRAP are naturally present on the surface of P. falciparum. They were selected for the vaccine because they contain multiple B, CD8, and CD4 epitopes known to be immunogenic. These antigenic sequences can be easily modified to include other vaccine variants if necessary. After vaccination target cells start to produce and secrete the composite antigen that can be presented on the surface of the cells-expressors and/or other neighboring cells secondarily targeted by the secreted vaccine.